Furthermore, our study group previously conducted a biomarker study of serum AREG in patients with HER2-positive breast cancer treated with trastuzumab plus taxane and found that high AREG levels were associated with poor clinical outcomes22. This evidence concerns the gene ERBB2 and breast cancer.